Omaveloxolone (RTA 408) for patients with mitochondrial myopathy
Full IRB Study Title:
A Phase 2 Study of the Safety, Efficacy and Pharmacodynamics of RTA 408 in the Treatment of Mitochondrial Myopathy
IRB Study ID: 408-C-1403
This study is closed.
For more information on this study, visit: https://clinicaltrials.gov/ct2/show/NCT02255422
Study Sponsor:
Reata Pharmaceuticals, Inc.
Who May Qualify:
Male or female mitochondrial myopathy patients 18 through 75 years of age.
We will screen potential study participants for additional criteria.
Who Does NOT Qualify:
For detailed information on qualifying for enrollment visit: https://clinicaltrials.gov/ct2/show/NCT02255422
Lead Investigator
Bruce H. Cohen, MD, FAAN
Chair, NeuroDevelopmental Science Center; Philip H. Maynard Chair in NeuroDevelopmental Science Fund; Chairman, American Academy of Neurology Advocacy Committee; Pediatric Neurologist
Pediatric Brain Tumor ProgramPediatric NeurologyMitochondrial Center
